Dexcom’s Stelo Continuous Glucose Monitor Now Available OTC In US

Dexcom announced the launch of Stelo, the first non-prescription continuous glucose monitoring system to hit the US market, but is likely going to face competition soon from Abbott.

• Source: Shutterstock

DexCom, Inc.’s Stelo continuous glucose monitor (CGM) became available in the US on 26 August for diabetics, prediabetics and healthy consumers alike, making it the first such product sold in the country that does not require a prescription.

While first to market, Dexcom is likely to face competition soon from its closest rival, Abbott , which is...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on HBW Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Business

Reckitt Leans On Europe As It Resets Mucinex In US

 
• By 

Decision to reformulate Mucinex sinus products without phenylephrine hits Reckitt's Q2 sales but the firm says it is preparing for upcoming cold & flu season with new marketing push.

EU Green Claims Directive: Commission Says It ‘Has Not Withdrawn’ From Negotiations

 
• By 

What's going on with the EU Green Claims Directive? HBW Insight speaks to the European Commission, Parliament and Council to find out why trilogue negotiations seem to have stalled.

Euro Q2 Consumer Health Earnings Preview: Reckitt, Haleon, Bayer

 
• By 

Major Europe-based consumer health players Reckitt, Haleon and Bayer feature in this sales and earnings preview, which highlights what to look out for as these three firms report their Q2 2025 results over the coming weeks.

People On The Move: Appointments at BioGaia, Assosalute, Bayer

 
• By 

A round-up of the latest European people moves: BioGaia hires new subsidiary head from L'Oréal; Assosalute gets new director; Bayer renews contract of CEO.

More from Beauty

Senate Appropriators Give US FDA More Non-User Fee Funds Than House

 

FDA would receive more funding for fiscal year 2026 in the Senate appropriations bill than its House counterpart, including $10m for unannounced foreign inspections.

Oral Care Marketer’s Claims Not Supported By Weight-of-Evidence, Holistic Approach – NARB

 

Essor Group, Inc., marketer of Boka toothpastes and mouthwash, failed to convince the National Advertising Review Board that a weight-of-the-evidence or holistic approach could support claims its products could ‘remineralize’ teeth.